Abstract

A major obstacle to the wide application of implantable glucose sensors is that the progressively lose function after a relatively short period of time in vivo. This is a result of tissue responses such as inflammation and fibrosis with resulting loss of vasculature as well as degradation of the sensor. Although our current Nafion-based glucose sensor displayed excellent stability in vitro, it rapidly calcified and degraded in vivo. The investigator hypothesizes that in vivo sensor performance can be enhanced by developing new membranes and by controlling the tissue interface by suppressing inflammation and fibrosis as well as increasing neovascularization.
Aim 1 will develop new membranes to replace Nafion, and also to develop novel surface hydrogels with tissue response modifiers (TRM's) to control fibrosis, inflammation, and neovascularization.
Aim 2 will develop biodegradable TRM delivery systems to control inflammation, fibrosis and neovascularization.
Aim 3 will evaluate in vitro and in vivo (rats), the developed sensors and components to determine performance, including life span.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Project (R01)
Project #
3R01RR014171-02S1
Application #
6294681
Study Section
Special Emphasis Panel (ZRG7 (45))
Program Officer
Jones, Teresa L Z
Project Start
1998-09-30
Project End
2001-09-29
Budget Start
1999-09-30
Budget End
2000-09-29
Support Year
2
Fiscal Year
2000
Total Cost
$27,237
Indirect Cost

  Institution

Name
University of Connecticut
Department
Type
Schools of Medicine
DUNS #
022254226
City
Farmington
State
CT
Country
United States
Zip Code
06030

  Publications

Galeska, Isabela; Kim, Tae-Kyoung; Patil, Siddhesh D et al. (2005) Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels. AAPS J 7:E231-40
Klueh, U; Seery, T; Castner, D G et al. (2003) Binding and orientation of fibronectin to silanated glass surfaces using immobilized bacterial adhesin-related peptides. Biomaterials 24:3877-84
Valdes, T I; Klueh, U; Kreutzer, D et al. (2003) Ex ova chick chorioallantoic membrane as a novel in vivo model for testing biosensors. J Biomed Mater Res A 67:215-23
Hickey, T; Kreutzer, D; Burgess, D J et al. (2002) Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 23:1649-56
Valdes, T I; Kreutzer, D; Moussy, F (2002) The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials. J Biomed Mater Res 62:273-82
Kim, Tae-Kyoung; Burgess, Diane J (2002) Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J Pharm Pharmacol 54:897-905
Hickey, T; Kreutzer, D; Burgess, D J et al. (2002) In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res 61:180-7
Galeska, I; Hickey, T; Moussy, F et al. (2001) Characterization and biocompatibility studies of novel humic acids based films as membrane material for an implantable glucose sensor. Biomacromolecules 2:1249-55
Kim, T K; Burgess, D J (2001) Formulation and release characteristics of poly(lactic-co-glycolic acid) microspheres containing chemically modified protein. J Pharm Pharmacol 53:23-31
Klueh, U; Goralnick, S; Bryers, J D et al. (2001) Binding and orientation of fibronectin on surfaces with collagen-related peptides. Student Research Award in the Masters Science Degree Candidate category, 27th annual meeting of the Society for Biomaterials, St. Paul, MN, April 24-29, 2001. J Biomed Mater Res 56:307-23

Showing the most recent 10 out of 12 publications